| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $88M | ||
| $62M |
Buys | $18,237,600 | 1 | 100 |
Sells | $0 | 0 | 0 |
| Fairmount Funds Management LLC | 1 | $18.24M | 0 | $0 | $18.24M |
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.
Over the last 12 months, insiders at Crescent Biopharma, Inc. have bought $18.24M and sold $0 worth of Crescent Biopharma, Inc. stock.
On average, over the past 5 years, insiders at Crescent Biopharma, Inc. have bought $4.65M and sold $3.34M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Fairmount Funds Management LLC () — $18.24M.
The last purchase of 1,360,000 shares for transaction amount of $18.24M was made by Fairmount Funds Management LLC () on 2025‑12‑04.
| 2025-12-04 | Fairmount Funds Management LLC | 1.36M 93.928% | $13.41 | $18.24M | -9.29% | |||
| 2024-08-08 | Sale | Invus Public Equities, L.P. | 10 percent owner | 260,873 0.2576% | $0.19 | $50,009 | +19.80% | |
| 2024-08-07 | Sale | Invus Public Equities, L.P. | 10 percent owner | 61,488 0.0577% | $0.18 | $11,197 | +28.87% | |
| 2024-08-06 | Sale | Invus Public Equities, L.P. | 10 percent owner | 55,732 0.0525% | $0.18 | $10,188 | +25.42% | |
| 2024-08-05 | Sale | Invus Public Equities, L.P. | 10 percent owner | 164,523 0.1596% | $0.19 | $30,996 | +22.08% | |
| 2024-08-02 | Sale | Invus Public Equities, L.P. | 10 percent owner | 286,200 0.2954% | $0.20 | $57,354 | +11.58% | |
| 2024-08-01 | Sale | Invus Public Equities, L.P. | 10 percent owner | 63,564 0.0708% | $0.22 | $13,743 | +4.05% | |
| 2024-07-30 | Sale | Invus Public Equities, L.P. | 10 percent owner | 756,835 0.861% | $0.22 | $167,185 | +3.10% | |
| 2024-07-29 | Sale | Invus Public Equities, L.P. | 10 percent owner | 363,949 0.4411% | $0.24 | $85,637 | -3.62% | |
| 2024-07-26 | Sale | Invus Public Equities, L.P. | 10 percent owner | 258,335 0.3216% | $0.24 | $62,440 | -5.56% | |
| 2024-06-21 | Rock Edwin | Chief Medical Officer | 115,000 0.1582% | $0.27 | $30,717 | -3.61% | ||
| 2024-06-20 | Rock Edwin | Chief Medical Officer | 190,000 0.2478% | $0.25 | $48,108 | -0.76% | ||
| 2024-06-18 | Hahn Brian M. | SVP Finance, CFO | 17,500 0.0223% | $0.25 | $4,335 | +2.67% | ||
| 2023-09-22 | Rock Edwin | Chief Medical Officer | 30,403 0.2249% | $1.38 | $41,956 | -0.71% | ||
| 2023-09-21 | Rock Edwin | Chief Medical Officer | 35,000 0.2706% | $1.38 | $48,300 | +2.17% | ||
| 2023-05-17 | Sale | Hahn Brian M. | SVP Finance, CFO | 3,700 0.0831% | $1.95 | $7,215 | -15.69% | |
| 2023-05-10 | JUNIUS DANIEL M | director | 30,000 0.5634% | $1.56 | $46,800 | -1.14% | ||
| 2023-05-08 | Johnson Bruce S | SVP & Chief Commercial Officer | 13,500 0.2673% | $1.57 | $21,195 | +18.24% | ||
| 2023-02-24 | Invus Public Equities, L.P. | 10 percent owner | 100,000 1.8736% | $1.70 | $170,000 | -5.03% | ||
| 2023-02-23 | Invus Public Equities, L.P. | 10 percent owner | 200,000 3.8707% | $1.75 | $350,760 | -5.85% |
| Fairmount Funds Management LLC | 2747866 9.9717% | $31.82M | 1 | 0 | ||
| Invus Public Equities, L.P. | 10 percent owner | 6317565 22.9256% | $73.16M | 8 | 9 | <0.0001% |
| BVF PARTNERS L P/IL | 10 percent owner | 4980812 18.0747% | $57.68M | 12 | 0 | <0.0001% |
| BARRIS PETER J | 10 percent owner | 4702791 17.0658% | $54.46M | 0 | 4 | |
| NEW ENTERPRISE ASSOCIATES 10 L P | 10 percent owner | 4702791 17.0658% | $54.46M | 0 | 2 | |
| BARRETT M JAMES | 4702791 17.0658% | $54.46M | 0 | 5 | ||
| SANDELL SCOTT D | director | 2237196 8.1185% | $25.91M | 0 | 10 | |
| Rock Edwin | Chief Medical Officer | 680403 2.4691% | $7.88M | 7 | 0 | <0.0001% |
| HENOS MICHAEL A | director | 469454 1.7036% | $5.44M | 2 | 4 | |
| Magnani John L. | SVP of Research, CSO | 366078 1.3285% | $4.24M | 1 | 4 | +31.85% |
| King Rachel K. | President, CEO | 356064 1.2921% | $4.12M | 0 | 1 | |
| Flynn James E | 10 percent owner | 305965 1.1103% | $3.54M | 0 | 3 | |
| Thackray Helen M. | SVP Clinical Development, CMO | 148615 0.5393% | $1.72M | 0 | 9 | |
| Johnson Bruce S | SVP & Chief Commercial Officer | 138980 0.5043% | $1.61M | 1 | 0 | |
| JUNIUS DANIEL M | director | 93250 0.3384% | $1.08M | 5 | 0 | +23.53% |
| Hahn Brian M. | SVP Finance, CFO | 70643 0.2564% | $818,045.94 | 2 | 3 | +31.85% |
| Andrews Patricia S | director | 45250 0.1642% | $523,995.00 | 1 | 0 | <0.0001% |
| Girard Armand | SVP, Chief Business Officer | 29161 0.1058% | $337,684.38 | 1 | 1 | +31.85% |
| deBethizy J Donald | President and CEO | 28926 0.105% | $334,963.08 | 0 | 17 | |
| Payne Fletcher | Chief Financial Officer | 25032 0.0908% | $289,870.56 | 1 | 0 | |
| Semerjian Harout | Chief Executive Officer | 25000 0.0907% | $289,500.00 | 1 | 0 | +31.85% |
| PEARSON TIMOTHY R | director | 24650 0.0895% | $285,447.00 | 1 | 0 | +31.85% |
| USMAN NASSIM | President & CEO | 24541 0.0891% | $284,184.78 | 7 | 0 | +5.98% |
| HILL STEPHEN A | director | 20711 0.0752% | $239,833.38 | 3 | 0 | |
| Goldberg Mark Alan | director | 11497 0.0417% | $133,135.26 | 1 | 0 | |
| SKALETSKY MARK B | director | 11332 0.0411% | $131,224.56 | 0 | 2 | |
| Williams Eddie | director | 10839 0.0393% | $125,515.62 | 1 | 0 | 0% |
| Blouse Grant E. | Chief Scientific Officer | 9417 0.0342% | $109,048.86 | 3 | 0 | +29.77% |
| Caldwell William S | SVP - Drug Discovery and Dev. | 7735 0.0281% | $89,571.30 | 0 | 23 | |
| Cai Veronica | Controller | 7353 0.0267% | $85,147.74 | 1 | 0 | +37.8% |
| Miller Seline E. | SVP Finance; Interim CFO & PAO | 6500 0.0236% | $75,270.00 | 2 | 0 | +102.5% |
| BROWN JULIA R | director | 6000 0.0218% | $69,480.00 | 2 | 4 | |
| Richard John P | director | 3716 0.0135% | $43,031.28 | 3 | 5 | +37.8% |
| Ling Geoffrey M.D. | director | 3000 0.0109% | $34,740.00 | 1 | 0 | <0.0001% |
| Musso Alan A | SVP, CFO & Treasurer | 2799 0.0102% | $32,412.42 | 0 | 23 | |
| Dunbar Geoffrey C | SVP, Clin. Dev. & Reg. Affairs | 1153 0.0042% | $13,351.74 | 0 | 24 | |
| Hodges Mauri K | VP Fin + Corp Sys & Controller | 1159 0.0042% | $13,421.22 | 0 | 10 | |
| Levy Howard | Chief Medical Officer | 639 0.0023% | $7,399.62 | 4 | 1 | <0.0001% |
| BLIXT CHARLES A | director | 0 0% | $0 | 0 | 2 | |
| SNYDERMAN RALPH | director | 0 0% | $0 | 0 | 1 | |
| BURRILL STEVEN | director | 0 0% | $0 | 0 | 3 | |
| LAWLOR AUGUSTINE | director | 0 0% | $0 | 0 | 1 | |
| Bencherif Merouane | SVP, Preclinical Research | 0 0% | $0 | 0 | 10 | |
| Brennan Jeffrey P | SVP - Bus. & Commercial Dev. | 0 0% | $0 | 0 | 7 | |
| DUNTON ALAN W | director | 0 0% | $0 | 0 | 4 | |
| Zorn Peter A | SVP, Lg Affrs, GC and Secrtary | 0 0% | $0 | 0 | 6 | |
| Hicks Karen A | VP Human Resources | 0 0% | $0 | 0 | 6 |
$69,151,774 | 71 | 24.96% | $329.51M | |
$5,911,307 | 70 | -1.38% | $351.73M | |
$24,436,687 | 43 | -29.99% | $319.49M | |
Crescent Biopharma, Inc. (CBIO) | $16,169,789 | 40 | 7.44% | $319.11M |
$64,487,106 | 32 | -22.92% | $302.49M | |
$1,447,973 | 17 | 13.95% | $318.93M | |
$10,399,379 | 13 | 13.60% | $299.73M | |
$112,952,085 | 11 | -19.19% | $349.91M | |
$13,043,783 | 8 | 732.82% | $308.05M | |
$119,804,612 | 8 | -17.22% | $288.38M | |
$91,549,696 | 8 | -6.55% | $352.78M | |
$603,645 | 8 | 57.40% | $343.99M | |
$2,342,954 | 7 | 3.82% | $347.17M | |
$17,675,244 | 7 | 92.20% | $308.82M | |
$1,346,998 | 7 | 25.06% | $315.23M | |
$208,592 | 4 | 11.22% | $357.92M | |
$2,720,023 | 3 | -11.76% | $334.11M | |
$4,888,000 | 3 | -20.50% | $291.15M | |
$37,067 | 3 | -89.81% | $296.52M |
| Increased Positions | 40 | +102.56% | 14M | +125.35% |
| Decreased Positions | 15 | -38.46% | 1M | -12.29% |
| New Positions | 23 | New | 7M | New |
| Sold Out Positions | 6 | Sold Out | 1M | Sold Out |
| Total Postitions | 64 | +64.1% | 24M | +113.06% |